[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575142":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":21,"responsibleParty":39,"collaborators":10,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":10,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"University of Leicester","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Participants with HFpEF",null,"Obese and non-obese participants with heart failure with preserved ejection fraction",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Gaurav S Gulsin, MBChB(Hons)","CONTACT","+44 (0)116 258 3038","gg149@le.ac.uk",{"name":19,"role":15,"phone":10,"phoneExt":10,"email":20},"Sarah L Ayton, MBBS","sa768@le.ac.uk",[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Glenfield Hospital, University Hospitals of Leicester","RECRUITING","Leicester","Leicestershire","LE3 9QP","United Kingdom","UK",{"type":31,"coordinates":32},"Point",[33,34],-1.13169,52.6386,{"lat":34,"lon":33},[37],{"name":19,"role":15,"phone":16,"phoneExt":10,"email":38},"sa768@leicester.ac.uk",{"type":40,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100575142","the-role-of-epicardial-adiposity-in-heart-failure-with-preserved-ejection-fraction-100575142",false,"NCT06768437","The Role of Epicardial Adiposity in Heart Failure With Preserved Ejection Fraction","EAT HFpEF","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study.\n* Aged ≥18 years old\n* Diagnosed with HFpEF by an experienced cardiologist or signs and symptoms of heart failure with a HFA-PEFF score ≥5\n* Able to understand written English\n\nExclusion Criteria:\n\n* LV ejection fraction \\\u003C45%\n* Recovered ejection fraction (previous ejection fraction \\\u003C40%) unless reduced ejection fraction was in context of tachycardia induced cardiomyopathy (eg atrial fibrillation\u002Fatrial flutter)\n* Severe primary valvular heart disease\n* HFpEF due to infiltrative cardiomyopathy (cardiac amyloidosis or sarcoidosis), genetic hypertrophic cardiomyopathy, restrictive cardiomyopathy\u002Fpericardial disease or congenital heart disease\n* Known heritable, idiopathic or drug-induced pulmonary arterial hypertension\n* Absolute contraindications to cardiac CT or MRI including estimated glomerular filtration rate (eGFR) ≤30ml\u002Fmin\u002F1.73m2. Patients with MRI-compatible devices are be excluded.\n* Women who are pregnant","ALL","18 Years",{"count":51,"type":52},130,"ESTIMATED","OBSERVATIONAL","In this study the investigators are aiming to recruit 130 patients with heart failure with preserved ejection fraction who are obese and non-obese to undergo CT and MRI scans, as well as some other investigations including blood tests, to help investigate if having more fat around the heart leads to worse heart function in this condition. This may lead to the development of new treatments aimed at lowering fat levels around the heart and in the rest of the body, specifically to treat HFpEF.",[56],"Heart Failure With Preserved Ejection Fraction (HFPEF)",[58,59,60,61],"Heart failure","Heart failure with preserved ejection fraction","Epicardial adipose tissue","Adiposity","2026-04-29",{"date":64,"type":65},"2026-04-30","ACTUAL",{"date":67,"type":65},"2025-02-12",{"date":69,"type":52},"2037-08",{"name":5,"class":6},1]